nodes	percent_of_prediction	percent_of_DWPC	metapath
Risedronate—Pneumonia—Bleomycin—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Risedronate—Muscular weakness—Carmustine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Risedronate—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Risedronate—Anaemia—Fludarabine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Risedronate—Infection—Teniposide—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Risedronate—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Risedronate—Herpes zoster—Methotrexate—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Risedronate—Muscular weakness—Vincristine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Risedronate—Pruritus—Mechlorethamine—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Risedronate—Cough—Fludarabine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Risedronate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Risedronate—Myalgia—Fludarabine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Risedronate—Arthralgia—Fludarabine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Risedronate—Haemoglobin—Bleomycin—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Risedronate—Haemorrhage—Bleomycin—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Risedronate—Dyspnoea—Teniposide—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Risedronate—Pneumonia—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Risedronate—Depression—Carmustine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Risedronate—Infection—Fludarabine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Risedronate—Vomiting—Mechlorethamine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Risedronate—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Risedronate—Urinary tract infection—Carmustine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Risedronate—Rash—Mechlorethamine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Risedronate—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Risedronate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Risedronate—Pneumonia—Vincristine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Risedronate—Depression—Vincristine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Risedronate—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Risedronate—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Risedronate—Bone disorder—Methotrexate—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Risedronate—Nausea—Mechlorethamine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Risedronate—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Risedronate—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Risedronate—Haemoglobin—Carmustine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Risedronate—Urticaria—Teniposide—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Risedronate—Glossitis—Methotrexate—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Risedronate—Haemorrhage—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Risedronate—Abdominal pain—Teniposide—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Risedronate—Body temperature increased—Teniposide—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Risedronate—Paraesthesia—Fludarabine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Risedronate—Dyspnoea—Fludarabine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Risedronate—Oedema peripheral—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Risedronate—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Risedronate—Dyspepsia—Fludarabine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Risedronate—Ulcer—Methotrexate—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Risedronate—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Risedronate—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Risedronate—Fatigue—Fludarabine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Risedronate—Inflammation—Methotrexate—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Risedronate—Constipation—Fludarabine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Risedronate—Pain—Fludarabine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Risedronate—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Risedronate—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Risedronate—Urethral disorder—Vincristine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Risedronate—Eye disorder—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Risedronate—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Risedronate—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Risedronate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Risedronate—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Risedronate—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Risedronate—Anaemia—Bleomycin—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Risedronate—Asthenia—Teniposide—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Risedronate—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Risedronate—Pruritus—Teniposide—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Risedronate—Arrhythmia—Carmustine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Risedronate—Cystitis—Methotrexate—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Risedronate—Cardiac disorder—Vincristine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Risedronate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Risedronate—Mental disorder—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Risedronate—Malnutrition—Carmustine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Risedronate—Cough—Bleomycin—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Risedronate—Angiopathy—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Risedronate—Diarrhoea—Teniposide—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Risedronate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Risedronate—Myalgia—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Risedronate—Chest pain—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Risedronate—Back pain—Carmustine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Risedronate—Mental disorder—Vincristine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Risedronate—Ecchymosis—Methotrexate—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Risedronate—Neoplasm—Methotrexate—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Risedronate—Bladder pain—Methotrexate—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Risedronate—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Risedronate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Risedronate—Infection—Bleomycin—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Risedronate—Anaemia—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Risedronate—Back pain—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Risedronate—Vomiting—Teniposide—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Risedronate—Asthenia—Fludarabine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Risedronate—Rash—Teniposide—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Risedronate—Dermatitis—Teniposide—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Risedronate—Headache—Teniposide—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Risedronate—Pruritus—Fludarabine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Risedronate—Back pain—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Risedronate—Anaemia—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Risedronate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Risedronate—Hypertension—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Risedronate—Nausea—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Risedronate—Anaemia—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Risedronate—Vertigo—Vincristine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Risedronate—Chest pain—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Risedronate—Myalgia—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Risedronate—Anxiety—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Risedronate—Paraesthesia—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Risedronate—Dyspnoea—Bleomycin—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Risedronate—Hypertension—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Risedronate—Myalgia—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Risedronate—Cough—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Risedronate—Infection—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Risedronate—Vomiting—Fludarabine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Risedronate—Rash—Fludarabine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Risedronate—Dermatitis—Fludarabine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Risedronate—Hypertension—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Risedronate—Pain—Bleomycin—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Risedronate—Headache—Fludarabine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Risedronate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Risedronate—Chest pain—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Risedronate—Myalgia—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Risedronate—Anxiety—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Risedronate—Infection—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Risedronate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Risedronate—Nervous system disorder—Vincristine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Risedronate—Nausea—Fludarabine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Risedronate—Infection—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Risedronate—Shock—Mitoxantrone—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Risedronate—Urticaria—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Risedronate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Risedronate—Insomnia—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Risedronate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Risedronate—Paraesthesia—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Risedronate—Dyspnoea—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Risedronate—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Risedronate—Insomnia—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Risedronate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Risedronate—Paraesthesia—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Risedronate—Pain—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Risedronate—Constipation—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Risedronate—Breast disorder—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Risedronate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Risedronate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Risedronate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Risedronate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Risedronate—Fatigue—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Risedronate—Asthenia—Bleomycin—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Risedronate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Risedronate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Risedronate—Constipation—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Risedronate—Pain—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Risedronate—Asthma—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Risedronate—Pruritus—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Risedronate—Fatigue—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Risedronate—Constipation—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Risedronate—Pain—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Risedronate—Abdominal pain—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Risedronate—Body temperature increased—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Risedronate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Risedronate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Risedronate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Risedronate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Risedronate—Body temperature increased—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Risedronate—Abdominal pain—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Risedronate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Risedronate—Hypersensitivity—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Risedronate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Risedronate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Risedronate—Pneumonia—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Risedronate—Vomiting—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Risedronate—Infestation NOS—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Risedronate—Infestation—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Risedronate—Depression—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Risedronate—Rash—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Risedronate—Dermatitis—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Risedronate—Asthenia—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Risedronate—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Risedronate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Risedronate—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Risedronate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Risedronate—Asthenia—Vincristine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Risedronate—Diarrhoea—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Risedronate—Nausea—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Risedronate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Risedronate—Dizziness—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Risedronate—Haemoglobin—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Risedronate—Diarrhoea—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Risedronate—Haemorrhage—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Risedronate—Pharyngitis—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Risedronate—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Risedronate—Urethral disorder—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Risedronate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Risedronate—Vomiting—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Risedronate—Dizziness—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Risedronate—Rash—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Risedronate—Dermatitis—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Risedronate—Headache—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Risedronate—Eye disorder—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Risedronate—Tinnitus—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Risedronate—Vomiting—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Risedronate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Risedronate—Rash—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Risedronate—Dermatitis—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Risedronate—Headache—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Risedronate—Nausea—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Risedronate—Angiopathy—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Risedronate—Vomiting—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Risedronate—Immune system disorder—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Risedronate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Risedronate—Rash—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Risedronate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Risedronate—Headache—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Risedronate—Mental disorder—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Risedronate—Malnutrition—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Risedronate—Nausea—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Risedronate—Nausea—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Risedronate—Back pain—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Risedronate—Anaemia—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Risedronate—Vertigo—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Risedronate—Cough—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Risedronate—Chest pain—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Risedronate—Myalgia—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Risedronate—Arthralgia—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Risedronate—Infection—Methotrexate—lymphatic system cancer	0.000986	0.000986	CcSEcCtD
Risedronate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Risedronate—Skin disorder—Methotrexate—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000904	0.000904	CcSEcCtD
Risedronate—Insomnia—Methotrexate—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Risedronate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000891	0.000891	CcSEcCtD
Risedronate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000885	0.000885	CcSEcCtD
Risedronate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Risedronate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000857	0.000857	CcSEcCtD
Risedronate—Fatigue—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Risedronate—Pain—Methotrexate—lymphatic system cancer	0.000849	0.000849	CcSEcCtD
Risedronate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
Risedronate—Urticaria—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Risedronate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000784	0.000784	CcSEcCtD
Risedronate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000784	0.000784	CcSEcCtD
Risedronate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Risedronate—Asthenia—Methotrexate—lymphatic system cancer	0.000712	0.000712	CcSEcCtD
Risedronate—Pruritus—Methotrexate—lymphatic system cancer	0.000702	0.000702	CcSEcCtD
Risedronate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000679	0.000679	CcSEcCtD
Risedronate—Dizziness—Methotrexate—lymphatic system cancer	0.000656	0.000656	CcSEcCtD
Risedronate—Vomiting—Methotrexate—lymphatic system cancer	0.000631	0.000631	CcSEcCtD
Risedronate—Rash—Methotrexate—lymphatic system cancer	0.000626	0.000626	CcSEcCtD
Risedronate—Dermatitis—Methotrexate—lymphatic system cancer	0.000625	0.000625	CcSEcCtD
Risedronate—Headache—Methotrexate—lymphatic system cancer	0.000622	0.000622	CcSEcCtD
Risedronate—Nausea—Methotrexate—lymphatic system cancer	0.000589	0.000589	CcSEcCtD
